Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

The Nifty 50 closed below the 22,800 mark for the first time since June 5, 2024, settling at 22,796, down 117 points. The Sensex also slipped 425 points to 75,311, while the Nifty Bank dropped 353 ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Of our top holdings, Lifecore faces the most uncertainty in "getting there." But why do we think the path exists? Click here ...

Pfizer shares surged 8.6% to Rs 4,448.35 after announcing a marketing and supply agreement with Mylan Pharmaceuticals for Ativan and Pacitane. The five-year deal aims to enhance distribution and ...

Formed in 2020 through the merger of Mylan and Upjohn, Viatris (NASDAQ ... Viatris delivered the slowest revenue growth of the whole group. The stock is down 4.8% since reporting and currently trades ...

The drugs are listed in alphabetical order. Aprepitant oral suspension: Merck reported a shortage of Emend, its aprepitant oral suspension. Merck did not provide a reason for the shortage. The ...

LXP is a $2.7 billion REIT in the industrial sector. The company's focus is on buying, developing and operating high-quality, ...

The Greenhaven Road Capital Main Fund returned ~13% during the quarter and ended up more than 27% for the full year. Click ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

Medication company Viatris (NASDAQ:VTRS) in Q4 CY2024, with sales falling 8.1% year on year to $3.53 billion. The company’s full-year revenue guidance of $13.75 billion at the midpoint came in 3.3% ...

For real-time, market-moving news join Investing Pro. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.